Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis

C. Vernieri, F. Galli, L. Ferrari, P. Marchetti, S. Lonardi, E. Maiello, R.V. Iaffaioli, M.G. Zampino, A. Zaniboni, S. De Placido, M. Banzi, A. Damiani, D. Ferrari, G. Rosati, R.F. Labianca, P. Bidoli, G.L. Frassineti, M. Nicolini, L. Pavesi, M.C. TronconiA. Buonadonna, S. Ferrario, G.L. Re, V. Adamo, E. Tamburini, M. Clerico, P. Giordani, F. Leonardi, S. Barni, A. Ciarlo, L. Cavanna, S. Gori, S. Cinieri, M. Faedi, M. Aglietta, M. Antista, K.F. Dotti, M. Di Bartolomeo, on behalf of TOSCA (Three or Six Colon Adjuvant) Investigators

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis'. Together they form a unique fingerprint.

Medicine & Life Sciences